A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
En randomisert, dobbeltmasket, multisenter, 3-arm pivotal fase 2/3-studie for å evaluere effektiviteten og sikkerheten til Intravitreal EYE103 sammenlignet med Intravitreal Ranibizumab (0,5 mg) hos deltakere med diabetisk makulaødem
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
CABA, Argentina, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentina, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentina, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentina, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Australia, 2640
- Albury, Australia
-
Parramatta, Australia, 2150
- Parramatta, Australia
-
Sydney, Australia, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Australia, 2135
- Sydney, Australia
-
-
-
-
-
Medellín, Colombia, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colombia, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760042
- Cali, Colombia
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Forente stater, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, Forente stater, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, Forente stater, 93309
- Bakersfield, CA
-
Glendale, California, Forente stater, 91204
- Glendale, CA
-
Modesto, California, Forente stater, 95356
- Modesto, CA
-
Mountain View, California, Forente stater, 94040
- Mountain View, CA
-
Redlands, California, Forente stater, 92374
- Redlands, CA
-
Sacramento, California, Forente stater, 95825
- Sacramento, CA
-
Sacramento, California, Forente stater, 95841
- Sacramento, CA
-
Santa Ana, California, Forente stater, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80909
- Colorado Springs, CO
-
Denver, Colorado, Forente stater, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Danbury, CT
-
Manchester, Connecticut, Forente stater, 06042
- Manchester, CT
-
Waterford, Connecticut, Forente stater, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, Forente stater, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, Forente stater, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, Forente stater, 33912
- Fort Myers,FL
-
Gainesville, Florida, Forente stater, 32607
- Gainesville, FL
-
Orlando, Florida, Forente stater, 32806
- Orlando, Florida
-
Plantation, Florida, Forente stater, 33324
- Plantation, FL
-
Sarasota, Florida, Forente stater, 34232
- Sarasota, FL
-
St. Petersburg, Florida, Forente stater, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, Forente stater, 32308
- Tallahassee, FL
-
Tampa, Florida, Forente stater, 33609-4614
- Tampa, FL
-
Tampa, Florida, Forente stater, 33617
- Tampa, FL
-
Winter Haven, Florida, Forente stater, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, Forente stater, 60439
- Lemont, IL
-
Springfield, Illinois, Forente stater, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, Forente stater, 66215
- Lenexa, Kansas
-
Wichita, Kansas, Forente stater, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, Forente stater, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, Forente stater, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, Forente stater, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, Forente stater, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, Forente stater, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, Forente stater, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, Forente stater, 13088
- Liverpool, NY
-
Oceanside, New York, Forente stater, 11572
- Oceanside, NY
-
Rochester, New York, Forente stater, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28803
- Asheville, NC
-
Hickory, North Carolina, Forente stater, 28602
- Hickory, NC
-
Wake Forest, North Carolina, Forente stater, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, Forente stater, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, Forente stater, 44130
- Cleveland, OH
-
Youngstown, Ohio, Forente stater, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, Forente stater, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, Forente stater, 97221
- Portland, OR
-
Springfield, Oregon, Forente stater, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, Forente stater, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, Forente stater, 29902
- Beaufort, SC
-
Florence, South Carolina, Forente stater, 29501
- Florence, SC
-
Ladson, South Carolina, Forente stater, 29456
- Ladson, SC
-
West Columbia, South Carolina, Forente stater, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Germantown, TN
-
Hixson, Tennessee, Forente stater, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, Forente stater, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, Forente stater, 37922
- Knoxville, TN
-
Nashville, Tennessee, Forente stater, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Forente stater, 79606
- Abilene, TX
-
Amarillo, Texas, Forente stater, 79109
- Amarillo, TX
-
Amarillo, Texas, Forente stater, 79106
- Amarillo, TX
-
Arlington, Texas, Forente stater, 76012
- Arlington, TX
-
Austin, Texas, Forente stater, 78705
- Austin, TX
-
Beaumont, Texas, Forente stater, 77707
- Beaumont, TX
-
Bellaire, Texas, Forente stater, 77401
- Bellaire, TX
-
Dallas, Texas, Forente stater, 75231
- Dallas, TX
-
Fort Worth, Texas, Forente stater, 76104
- Fort Worth, TX
-
Katy, Texas, Forente stater, 77494
- Katy, TX
-
Plano, Texas, Forente stater, 75075
- Plano, TX
-
Round Rock, Texas, Forente stater, 78681
- Round Rock, TX
-
San Antonio, Texas, Forente stater, 78240
- San Antonio, TX
-
Schertz, Texas, Forente stater, 78154
- Schertz, Texas
-
The Woodlands, Texas, Forente stater, 77384
- The Woodlands, TX
-
Willow Park, Texas, Forente stater, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, Forente stater, 24502
- Lynchburg, VA
-
Richmond, Virginia, Forente stater, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, Forente stater, 99204
- Spokane, WA
-
-
-
-
-
Créteil, Frankrike, 94010
- Creteil, France
-
Lyon, Frankrike, 69004
- Lyon, France
-
Marseille, Frankrike, 13008
- Marseille, France
-
Paris, Frankrike, 75006
- Paris, France
-
Paris, Frankrike, 75015
- Paris, France
-
Paris, Frankrike, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, Frankrike, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, Frankrike, 21079
- Cedex, France
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Beer Yakov, Israel
-
Haifa, Israel, 3436212
- Haifa, Israel
-
Jerusalem, Israel, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israel, 49100
- Petah Tikva, Israel
-
Rehovot, Israel, 76100
- Rehovot, Israel
-
Tel Aviv, Israel, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Italia, 40138
- Bologna, Italy
-
Florence, Italia, 50139
- Firenze, Italy
-
Milan, Italia, 20122
- Milano, Italy
-
Milan, Italia, 20132
- Milano, Italy
-
Milan, Italia, 20157
- Milano, Italy
-
Roma, Italia, 00168
- Roma, Italy
-
Rome, Italia, 81.00133
- Rome, Italy
-
Udine, Italia, 33100
- Udine, Italy
-
-
-
-
-
Osijek, Kroatia, 31000
- Osijek, Croatia
-
-
-
-
-
Riga, Latvia, LV1002
- Riga, Latvia
-
Riga, Latvia, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Polen, 15-866
- Bialystok, Poland
-
Bydgoszcz, Polen, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Polen, 85-631
- Bydgoszcz, Poland
-
Gdansk, Polen, 80-809
- Gdansk, Poland
-
Katowice, Polen, 40-594
- Katowice, Poland
-
Krakow, Polen, 31-501
- Krakow, Poland
-
Olsztyn, Polen, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Polen, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Polen, 80-809
- Gdansk, Poland
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Portugal, 4200-319
- Porto, Portugal
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Trebišov, Slovakia, 075 01
- Trebisov, Slovakia
-
Trenčín, Slovakia, 911 01
- Trencin, Slovakia
-
Žilina, Slovakia, 012 07
- Zilina, Slovakia
-
-
-
-
-
Barcelona, Spania, 08035
- Barcelona, Spain
-
Barcelona, Spania, 08021
- Barcelona, Spain
-
Barcelona, Spania, 08022
- Barcelona, Spain
-
Barcelona, Spania, 08195
- Barcelona, Spain
-
Santiago de Compostela, Spania, 15706
- Santiago de Compostela, Spain
-
Seville, Spania, 41009
- Sevilla, Spain
-
Zaragoza, Spania, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, Spania, 46100
- Valencia, Spain
-
-
-
-
-
Bradford, Storbritannia, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Storbritannia, BS1 2LX
- Bristol, UK
-
Liverpool, Storbritannia, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Storbritannia, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Storbritannia, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Storbritannia, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Storbritannia, YO10 4DZ
- York, United Kingdom
-
-
-
-
-
Mladá Boleslav, Tsjekkia, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Tsjekkia, 547 01
- Nachod, Czechia
-
Prague, Tsjekkia, 1150/50
- Prague, Czechia
-
Prague, Tsjekkia
- Prague, Czechia
-
-
-
-
Turkey
-
Ankara, Turkey, Tyrkia (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Tyrkia (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Tyrkia (Türkiye), 35330
- Balcova, Turkey
-
-
-
-
-
Frankfurt, Tyskland, 60590
- Frankfurt, Germany
-
Hanover, Tyskland, 30625
- Hanover, Germany
-
München, Tyskland, 80336
- Munchen, Germany
-
Münster, Tyskland, 48145
- Munster, Germany
-
-
-
-
-
Budapest, Ungarn, H-1062
- Budapest, Hungary
-
Budapest, Ungarn, H-1085
- Budapest, Hungary
-
Budapest, Ungarn, H-1106
- Budapest, Hungary
-
Budapest, Ungarn, H-1133
- Budapest, Hungry
-
Debrecen, Ungarn, H-4032
- Debrecen, Hungary
-
Pécs, Ungarn, H-7621
- Pecs, Hungary
-
Szeged, Ungarn, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Ungarn, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Graz, Østerrike, 8036
- Graz, Austria
-
Innsbruck, Østerrike, 6020
- Innsbruck, Austria
-
Vienna, Østerrike, 1090
- Vienna, Austria
-
Vienna, Østerrike, 1140
- Vienna, Austria
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andre navn:
|
|
Eksperimentell: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andre navn:
|
|
Aktiv komparator: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Tidsramme: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Tidsramme: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Tidsramme: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Tidsramme: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Tidsramme: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Tidsramme: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Tidsramme: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Tidsramme: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Tidsramme: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Charles Miller, MD PhD, EyeBiotech Ltd.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- EYE-RES-102
- MK-3000-001 (Annen identifikator: MSD)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .